Paclitaxel, an Active Agent in Nonsquamous Carcinomas of the Uterine Cervix: A Gynecologic Oncology Group Study

Authors:
  • JBJohn A. Blessing
    John A. Blessing
  • KWKenneth D. Webster
    Kenneth D. Webster
  • PRPeter G. Rose
    Peter G. Rose
  • AMAllan R. Mayer
    Allan R. Mayer
  • WFWesley C. Fowler
    Wesley C. Fowler
  • JMJohn H. Malfetano
    John H. Malfetano
  • RARonald D. Alvarez
    Ronald D. Alvarez

Abstract
PURPOSE: A phase II trial of paclitaxel was initiated in advanced nonsquamous carcinoma of the cervix to determine its activity in patients who had failed standard chemotherapy. PATIENTS AND METHODS: Eligible patients had at least one measurable lesion. The starting dose of paclitaxel was 170 mg/m2 (135 mg/m2 for patients with prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated every 3 weeks. Dose escalation to 200 mg/m2 and de-escalation to 110 mg/m2 were allowed based on adverse effects. RESULTS: In this trial, 42 assessable patients were initially entered onto the study, and 13 responses were seen; four patients had a complete response, and nine patients had a partial response. The overall response rate was 31%. The primary and dose-limiting toxicity was neutropenia. CONCLUSION: The response rate to paclitaxel exceeds the rates reported using other single agents in nonsquamous carcinoma of the cervix.

This publication has 10 references indexed in Scilit: